You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.
CNN reports Johnson & Johnson is seeking an emergency authorization for its SARS-CoV-2 vaccine in the US.
Johnson & Johnson says its candidate SARS-CoV-2 vaccine has 66 percent efficacy rate in preventing moderate-to-severe COVID-19, according to NPR.
Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.
Two coronavirus vaccine trials that had been paused in the US have resumed.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
Stat News reports Johnson & Johnson has paused its SARS-CoV-2 vaccine trial due to an unexplained illness affecting a study participant.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.